Taglich's Company Profile for:


Receive email alerts
 for this company
 

    

Competitive Technologies, Inc.
Symbol: CTT
Analyst: Juan Noble
Taglich Rating: Speculative Buy
Price Target: $4.00
Time Horizon: 12 Months
Rating Established: June 18, 2010
Price When Established: $2.21
Most Recent Report: June 18, 2010
Price When Issued: $2.21

Most Recent Update

Initial Research Report (Dated June 18, 2010)

What's New

On September 2, 2010, Competitive Technologies announced that on September 3, 2010, the company’s common stock will trade under the ticker symbol CTTC on the over the counter market. Previously, the stock traded under the symbol CTT.

On August 30, 2010 Competitive Technologies announced that starting September 3, 2010 its common stock is expected to trade on the Over-the-Counter Bulletin Board (OTC BB).

Subsequent to the August 25, 2010 oral hearing before the Exchange's Listing Qualifications Panel, the Exchange affirmed its decision to delist the CTT’s securities primarily due to continued losses and low equity.

Competitive Technologies will follow the formal application procedures and notify investors as soon as possible of the new trading symbol and the final status of the fund raise with the Crisnic Fund that was announced June 2, 2010.

On July 19, 2010, Competitive Technologies announced that it anticipates fourth quarter (ends July 31, 2010) revenue of $1 million from sales of the MC5-A (Calmare Pain Therapy) device.

We projected 4QFY10 revenue of $718,000, almost all of that from sales of the MC5-A. In the year-earlier quarter, revenue totaled $48,500, only $800 of that from product sales.

Company Description

Competitive Technologies, Inc. (NYSE-AMEX: CTT), headquartered in Fairfield, Connecticut, offers technology transfer services. CTT licenses technologies from clients, obtaining licenses or rights to intellectual property on a broad array of technologies from universities, companies, inventors and patent or intellectual property holders. The company’s intellectual property portfolio includes rights to technology in life sciences (healthcare), electronics, nano science and physical sciences.

Licenses and rights licensed by CTT from clients are in turn licensed or sub-licensed to customers, including large multinationals seeking to augment their product development efforts and enlarge their pipelines. Customers pay CTT license fees, royalties, or a share of per procedure or per unit revenue. Since its inception, CTT has licensed nearly 500 technologies to corporations and shared over $100 million in shared technology revenues with universities and inventors.

Near-term growth efforts are based on the commercialization of a medical device that CTT acquired rights to in 2007. The product, FDA-approved and CE marked, is eligible for regulatory clearance in most of the world’s medical markets. The MC5-A, also known as the Calmare Pain Therapy device, could potentially gain wide acceptance as a treatment for neuropathic and oncologic pain that has not responded to pharmaceutical or other device-based pain therapy.

Taglich Research Reports

All Research Reports are in Adobe Acrobat format.
( For the latest Adobe Acrobat reader click here)

The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. The company paid for the creation and dissemination of research reports for the first month a monetary fee of $2,000 (USD) in April 2010, and after the first month following publication will pay a monthly monetary fee of $2,000 (USD) to Taglich Brothers, Inc. for such services. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.

Send to a Friend

To send this page to a friend, just fill out the form below
and press the "send it" button!

Your Name:
Your E-mail:
 Please send me a copy
Your Friend's Name:
Your Friend's E-mail:
All fields are required